Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25

Jazz Pharmaceuticals plc

2026-Q1 EPS reported $4.43 revenue$1,068,900,000

Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.
Xywav net product sales $408M (+18% YoY) with 425 net patient adds; Epidiolex grew 15% YoY.
Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review; PDUFA date Aug 25, 2026.
Company reaffirms 2026 revenue and expense guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jazz Pharmaceuticals plc reported first quarter of 2026 (1Q26) results: revenue $1.1 billion, EPS $4.43 / $6.34. Guidance reaffirmed.

Period: first quarter of 2026 (1Q26)
Revenue: $1.1 billion
EPS: $4.43 / $6.34
Guidance: reaffirmed
Result: reported results

Exact text from the filing

filing. --- EX-99.1 (EX-99.1) --- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ®

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001232524-26-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.